At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 350 enrolled
Drug / intervention
Fluticasone propionate +2 moredrug
Likely dose
Fluticasone propionate 250 µgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomised, Double-blind, Double-dummy, Placebo Controlled (With Rescue Medication), Multicenter Study to Evaluate the Efficacy and Safety of Fluticasone Furoate Inhalation Powder in the Treatment of Persistent Asthma in Adults and Adolescents.
In Brief
A Phase 3 clinical trial evaluating Fluticasone propionate, Fluticasone furoate, and 1 other intervention for Asthma. Completed, enrolled 350 participants across 82 sites in 5 countries.
Detailed Summary
A randomised, double-blind, double-dummy, placebo controlled (with rescue medication), multicenter study to evaluate the efficacy and safety of Fluticasone Furoate inhalation powder in the treatment of persistent asthma in adults and adolescents.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma
CountriesBelgium, Germany, Poland, Romania, United States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartJun 2010
First PostedJul 2010
Primary CompletionJan 2012
Study CompletionJan 2012
TodayJul 2026
First PostedJul 12, 2010
Enrollment StartJun 30, 2010
Primary CompletionJan 1, 2012
Study CompletionJan 16, 2012
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 16.0 years ago
Interventions
Fluticasone propionatedrug
Fluticasone propionate inhalation powder, 250 µg
Fluticasone furoatedrug
Fluticasone furoate inhalation powder, 100 µg
Placebodrug
Placebo inhalation powder